Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007465)
Pfizer Foundation (Fellowship in Dermatology Patient Oriented Research)
Article History
Received: 14 April 2020
Accepted: 11 May 2020
First Online: 3 June 2020
Compliance with Ethical Standards
:
: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
: Dr. Mostaghimi receives consulting fees from Pfizer, hims, and 3derm. He has equity in Lucid and hims and receives licensing fees from Pfizer. He is on the medical advisory board for hims. He is a clinical trial investigator for Incyte, Lilly, Aclaris, and Concert. The authors have no other conflicts of interest to disclose.
Free to read: This content has been made available to all.